In Vivo Toxicology Market

In Vivo Toxicology Market by Product (Animal Models, Reagents & Kits), Test Type (Chronic, Sub-acute), Toxicity Endpoints (Systemic, Immunotoxicity), Testing Facility (Outsourced, In-house), End User (Academic & Research Institute, CROs) - Forecast to 2025

Report Code: BT 6000 Mar, 2021, by marketsandmarkets.com

[167 Pages Report] The global in vivo toxicology market size is projected to reach USD 6.6 billion by 2025 from USD 5.0 billion in 2020, at a CAGR of 5.5% during the forecast period. Market growth is driven largely by the increasing pharmaceutical R&D activities, innovations in animal models, the development of exclusive in vivo toxicology tests, and the increasing demand for personalized medicine.

In Vivo Toxicology Market

To know about the assumptions considered for the study, download the pdf brochure

Covid-19 Impact On The Global In Vivo Toxicology Market

The COVID-19 outbreak is an unprecedented global public health challenge that is expected to significantly impact the in vivo toxicology market, especially due to the growing focus on vaccine development. According to the WHO, more than 20 vaccines are being developed across the globe for COVID-19. These vaccines are in the preclinical phase, and some of them have already entered the animal trial phase. Several animal models, particularly mice models, have supported the replication of SARS-CoV-2, including C57BL/6, BALB/c, 129SvEv, hACE2 transgenic, and STA1 gene knockout (KO); some of these, like humans, developed symptoms of pneumonia.

The market demand for COVID-19 animal models is increasing, especially for humanized ACE2 (hACE2) mice, which express human ACE2 in the airway and other epithelia and develop a lethal SARS-CoV infection. However, the current supply is limited, as animal model providers do not have readymade populations to meet surging demand.

In the short term, the pandemic is anticipated to harm the in vivo toxicology market. However, governments and scientific research institutions are bound to increase research investments in treatments and vaccines. Some animal model providers, such as The Jackson Laboratory and Cyagen, have prioritized the production of ACE2 mice to support research on COVID-19. The surging demand for therapeutics and vaccines against COVID-19 is expected to boost the in vivo toxicology market during the forecast period

In Vivo Toxicology Market Dynamics

Driver: Increasing pharmaceutical R&D activities

Changing dynamics in the healthcare markets across the globe have compelled pharmaceutical and biotechnology companies to develop products that offer real value rather than just incremental benefits. Owing to this, an increasing number of pharma companies and medical device manufacturers focus on innovation and increasing their R&D efficiencies.

R&D activities, however, are associated with a high risk of failure. One estimate is that for every 10,000 compounds synthesized in the discovery phase, only 250 reach the preclinical phase, ultimately resulting in one approved drug by the FDA (Source: National Center for Biotechnology Information). Thus, it is very important to bring down the attrition of failing molecules in the early stages of drug development. The primary goal of R&D is to increase the overall likelihood of approval of Phase I candidates by increasing the acceptance of the compounds in the preclinical stages. To achieve this, intensive R&D is conducted in the early stages of drug development. Increased R&D investments in the initial stages of drug development are likely to increase the use of in vivo toxicology methods before the drug reaches the more expensive clinical stage.

According to the Biotechnology Industry Organization (BIO) 2019, nearly 82.7% of the venture capital investment in the US by emerging growth companies (EGCs) over the last decade was in R&D for emerging therapeutics and novel drugs. Likewise, ~50% of the venture capital investment for therapeutics was for developing biologic molecules/metabolites. Companies are also investing in research to develop breakthrough molecules/metabolites to cater to growing demands in the healthcare industry

Restraints: Alternatives to animal testing

Research scientists and toxicology experts are trying to find alternatives to animal testing due to pressure from animal welfare communities such as PETA. Researchers are trying to replace, reduce, or refine (3Rs) animal use in in vivo toxicology testing. Tests should satisfy the validation criteria established by the Organisation for Economic Co-operation and Development (OECD), the European Centre for the Validation of Alternative Methods (ECVAM), and the Interagency Coordinating Committee on the Validation of Alternative Methods (ICCVAM).

Some alternative tests include:

  • In vitro tests: These tests are performed in laboratories in a controlled environment outside of a living organism using various lab equipment
  • Ex vivo tests: These tests are performed in or on tissues from organisms in an external environment with minimal alteration of natural conditions
  • In silico tests: These tests are performed using computer simulation

In vitro studies are increasingly gaining importance in the toxicology testing of drugs. Improved non-animal in vitro models are available in the market, and new technologies used in toxicology testing (including cell culture models, human stem cells, high-throughput testing, imaging technologies, and integrated test strategies) help to generate and interpret new types of non-animal data. A key example of companies switching to alternative methods is Envigo. In 2015, the company conducted in vitro and in silico tests to reduce animal use in toxicology studies. The company developed in vitro ion-channel tests for measuring the cardiac risk of pharmaceuticals. The increasing adoption of alternative methods for toxicology testing is expected to limit the demand for animal models in the coming years, which, in turn, will impact the in vivo toxicology market.

Opportunity: Rising demand for humanized animal models

Humanized animal models are important tools for conducting preclinical research to gain insights into human biology. These models are developed through the engraftment of human cells or tissues, leading to the expression of human proteins in animals.

Humanized mice are increasingly being used as models for biomedical research applications, such as cancer, infectious diseases, HIV/AIDS, regenerative medicine, and hepatitis. In March 2019, the National Institute of Allergy and Infectious Diseases (NIAID), an agency of the US Department of Health and Human Services, announced funding for projects to conduct detailed characterization, direct comparisons, and further development of humanized immune system (HIS) mouse models. The need to identify the actual effects of drugs on humans, as well as the growing focus on studying human-specific infections, therapies, and immune responses, is promoting the development and use of humanized animal models

By Product, the consumables accounted for the largest share of the in vivo toxicology market

Based on the product, the in vivo toxicology market is categorized into instruments and consumables. The consumables segment is further categorized into animal models and reagents & kits. Animal models is sub segmented into mice, rat and other animals. The consumables segment accounted for the largest share of the in vivo toxicology market in 2019. The widespread use of reagents & kits in research activities, increase in funds for research projects, and their extensive application in the in vivo toxicology studies are fueling the growth of this segment.

By toxicity endpoint, the immunotoxicity segment accounted for the largest share of the in vivo toxicology market

Based on toxicity endpoint, the global in vivo toxicology market is segmented into immunotoxicity, systemic toxicity, carcinogenicity, genotoxicity, developmental & reproductive toxicity (DART), and other toxicity endpoints (includes organ toxicity, endocrine disruptor toxicity, juvenile toxicity, phototoxicity, ocular toxicity, and skin irritation). In 2019, the immunotoxicity segment accounted for the largest share of the global in vivo toxicology market, followed by the systemic toxicity segment.The rising demand for the development of biologics and biosimilars is driving the growth of the immunotoxicity segment

By test type, chronic test type segment accounted for the largest share of the in vivo toxicology market

Based on test type, the global in vivo toxicology market is segmented into acute, sub-acute, sub-chronic, and chronic test type. The chronic test type segment is expected to dominate the market during the forecast period. In 2019, the chronic test type segment held the largest share of  the market, followed by sub-chronic test type.Increasing research on drugs used for longer-duration therapy such as anti-cancer, anti-convulsive, anti-arthritis, and anti-hypertensives drives the growth of the chronic test type market.

By testing facility, outsourced testing facilities segment accounted for the largest share of the in vivo toxicology market

Based on the testing facility, the global in vivo toxicology market is segmented into outsourced testing facilities and in-house testing facilities. The outsourced testing facilities segment is expected to dominate the market, by testing facility, over the forecast period. In 2019, the outsourced testing facilities segment held the largest share  of the global in vivo toxicology market. The large share of this segment is attributed to the increasing R&D investments and cost-saving strategies of pharmaceutical, biopharmaceutical, and medical devices companies, resulting in increased outsourcing of services to CROs

By end user, academic and research institutes segment accounted for the largest share of the in vivo toxicology market

Based on the end user, the global in vivo toxicology market has been broadly segmented into academic & research institutes, pharmaceutical & biotechnology companies, contract research organizations, and other end users (cosmetic companies and food laboratories). The academic and research institutes segment accounted for the largest share of the in vivo toxicology market in 2019. The increasing number of research activities in the field of in vivo toxicology and funding to the academic and research institutes to conduct in vivo toxicology research are the factors responsible for the largest share of the segment

North America accounted for the largest share of the in vivo toxicology market in 2019

North America, which includes the US and Canada, accounted for the largest share of the in vivo toxicology market. The large share of the North America region can be attributed to the presence of major players operating in the in vivo toxicology market in the US, growing biomedical research in the US, and rising preclinical activities by CROs and pharmaceutical companies in the region.

In Vivo Toxicology Market  by Region

Key Market Players

The major players operating in this market are by Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia), Harbour BioMed (US) among others.

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market Size Available for Years

2018–2025

Base Year Considered

2019

Forecast Period

2020–2025

Forecast Units

Value (USD Billion)

Segments Covered

Product, Test Type,Toxicity End Point,Testing Facility, End User, and Region

Geographies Covered

North America, Europe, Asia Pacific, Latin America and Middle East & Africa

Companies Covered

Charles River Laboratories (US), The Jackson Laboratory (US), Envigo (US), Taconic Biosciences, Inc. (US), and JANVIER LABS (France), Thermo Fisher Scientific (US), Danaher Corporation (US), Waters Corporation (US), Agilent Technologies (US), Shimadzu Corporation (Japan), Bruker Corporation (US), PerkinElmer (US). Other prominent players include Merck KGaA (Germany), GE Healthcare (US), and Bio-Rad Laboratories (US), genOway (France), Cyagen Biosciences (US), GVK BIO (India), PolyGene (Switzerland), Crown Biosciences (US), TransCure bioServices (France), Ozgene Pty Ltd. (Australia), Harbour BioMed (US)  (Total 23 companies)

The study categorizes the in vivo toxicology market into the following segments and subsegments:

  • By Product
    • Instruments
    • Consumables
      • Reagents & Kits
      • Animal Models
        • Mice Models
        • Rat Models
        • Other Animal Models (Guinea Pigs, Hamsters, Rabbits, and Human Primates)
  • By Test Type
    • Acute
    • Sub-acute
    • Sub-chronic
    • Chronic test type
  • By Testing facility
    • outsourced testing facility
    • In-house testing facility
  • By Toxicity End Point
    • Immunotoxicity
    • Systemic toxicity
    • Carcinogenicity
    • Genotoxicity
    • Developmental & reproductive toxicity (DART)
    • Other toxicity endpoints
  • By End User
    • Academic and Research Institutes
    •  Pharmaceutical & Biotechnology Companies
    •  Contract Research Organizations
    •  Other End Users
  • Company Type
    • Tier 1 Pharmaceutical Companies
    • Tier 2 Pharmaceutical Companies
    • Tier 3 Pharmaceutical Companies
  • By Region
    • North America
      • US
      • Canada
    • Europe
      • Germany
      • France
      • UK
      • Italy
      • Spain
      • Rest of Europe
    • Asia Pacific
      • Japan
      • China
      • India
      • Rest of Asia Pacific
    • Latin America
      • Brazil
      • Mexico
    • The Middle East and Africa

Recent Developments

  • In 2020, GenOway acquired exclusive worldwide rights from Merck for its foundational CRISPR/Cas9 portfolio in the rodent field.
  • In 2020, Taconic entered into an agreement with the University of Texas Medical Branch to distribute humanized ACE2 mice for COVID-19 research.
  • In 2020, The Jackson Laboratory started the production of ACE2 mice to support the research on COVID-19.
  • In 2020, Danaher Corporation acquired GE Healthcare’s Life Sciences business.
  • In 2020, Thermo Fisher launched Orbitrap Exploris 240 and Orbitrap Exploris 120 mass spectrometers.
  • In 2020, Waters Corporation announced the establishment of Immerse Cambridge, a research laboratory in the heart of Cambridge’s Kendall Square. Immerse Cambridge will serve as a strategic, collaborative space in the community, where Waters can partner with academia and research to accelerate the next generation of scientific advancements.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 38)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           FIGURE 1 IN VIVO TOXICOLOGY MARKET SEGMENTATION
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 42)
    2.1 RESEARCH DATA
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
           FIGURE 2 BREAKDOWN OF PRIMARIES: IN VIVO TOXICOLOGY MARKET
           2.1.3 MARKET DATA ESTIMATION & TRIANGULATION
           FIGURE 3 DATA TRIANGULATION METHODOLOGY
    2.2 MARKET ESTIMATION METHODOLOGY
           FIGURE 4 MARKET SIZE ESTIMATION (COMPANY REVENUE ANALYSIS-BASED ESTIMATION)
           FIGURE 5 IN VIVO TOXICOLOGY MARKET SIZE (USD MILLION)
           FIGURE 6 IN VIVO TOXICOLOGY MARKET: GROWTH RATE OF TOP COMPANIES (2017−2019)
           FIGURE 7 IN VIVO TOXICOLOGY MARKET: FINAL CAGR PROJECTIONS (2020−2025)
           FIGURE 8 IN VIVO TOXICOLOGY MARKET: CAGR PROJECTIONS FROM THE ANALYSIS OF DEMAND-SIDE DRIVERS AND OPPORTUNITIES
    2.3 INDUSTRY INSIGHTS
    2.4 ASSUMPTIONS FOR THE STUDY

3 EXECUTIVE SUMMARY (Page No. - 49)
           FIGURE 9 IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2020 VS. 2025 (USD MILLION)
           FIGURE 10 IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2020 VS. 2025 (USD MILLION)
           FIGURE 11 GEOGRAPHICAL SNAPSHOT OF THE IN VIVO TOXICOLOGY MARKET

4 PREMIUM INSIGHTS (Page No. - 52)
    4.1 IN VIVO TOXICOLOGY MARKET OVERVIEW
           FIGURE 12 INCREASING PHARMACEUTICAL R&D ACTIVITIES TO DRIVE MARKET GROWTH
    4.2 IN VIVO TOXICOLOGY MARKET SHARE, BY TOXICITY ENDPOINT, 2020 VS. 2025
           FIGURE 13 IMMUNOTOXICITY SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2025
    4.3 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2020 VS. 2025 (USD MILLION)
           FIGURE 14 OUTSOURCED TESTING FACILITIES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
    4.4 IN VIVO TOXICOLOGY MARKET SHARE, BY END USER, 2020 VS. 2025
           FIGURE 15 ACADEMIC & RESEARCH INSTITUTES ARE THE LARGEST END USERS OF IN VIVO TOXICOLOGY PRODUCTS

5 MARKET OVERVIEW (Page No. - 54)
    5.1 MARKET DYNAMICS
           FIGURE 16 IN VIVO TOXICOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.1.1 DRIVERS
                    5.1.1.1 Increasing pharmaceutical R&D activities
           TABLE 1 R&D INVESTMENTS OF NOTE
                    5.1.1.2 Innovations in animal models
           TABLE 2 INNOVATIVE ANIMAL MODELS DEVELOPED AND LAUNCHED BY PLAYERS
                    5.1.1.3 Exclusive in vivo toxicology tests
                    5.1.1.4 Increasing demand for personalized medicine
           5.1.2 RESTRAINTS
                    5.1.2.1 Alternatives to animal testing
           5.1.3 OPPORTUNITIES
                    5.1.3.1 Rising demand for humanized animal models
           5.1.4 CHALLENGES
                    5.1.4.1 Regulations and laws for the ethical use of animals in research
    5.2 IMPACT OF COVID-19 ON THE VIVO TOXICOLOGY MARKET
    5.3 REGULATORY ASSESSMENT
           5.3.1 INTRODUCTION
           5.3.2 NORTH AMERICA
           5.3.3 EUROPE
           5.3.4 CHINA
           5.3.5 JAPAN
           5.3.6 INDIA
           5.3.7 AUSTRALIA
           5.3.8 BRAZIL
    5.4 PATENT ANALYSIS
           5.4.1 TOP EIGHT INSTITUTES WITH THE HIGHEST NO. OF PATENT FILINGS FOR ANIMAL MODELS IN THE LAST 10 YEARS
           5.4.2 TOP 20 ACTIVE COUNTRIES IN PATENT FILING (ANIMAL MODELS) IN THE LAST 10 YEARS
           5.4.3 FIELD OF STUDY IN PATENT FILING (ANIMAL MODELS) IN THE LAST 10 YEARS
    5.5 TRADE ANALYSIS
           5.5.1 TRADE ANALYSIS FOR CHROMATOGRAPHY AND ELECTROPHORESIS INSTRUMENTS
           TABLE 3 IMPORT DATA FOR ELECTROPHORESIS AND CHROMATOGRAPHY INSTRUMENTS, BY COUNTRY, 2016–2020 (USD THOUSAND)
           5.5.2 TRADE ANALYSIS FOR DIAGNOSTIC AND LABORATORY REAGENTS
           TABLE 4 IMPORT DATA FOR DIAGNOSTIC AND LABORATORY REAGENTS, BY COUNTRY, 2016-2020 (USD THOUSAND)
    5.6 PORTER’S FIVE FORCES ANALYSIS
           TABLE 5 PORTER’S FIVE FORCES ANALYSIS
           5.6.1 THREAT OF NEW ENTRANTS
           5.6.2 THREAT OF SUBSTITUTES
           5.6.3 BARGAINING POWER OF SUPPLIERS
           5.6.4 BARGAINING POWER OF BUYERS
           5.6.5 INTENSITY OF COMPETITIVE RIVALRY
    5.7 SUPPLY CHAIN ANALYSIS
           FIGURE 17 DIRECT DISTRIBUTION STRATEGY PREFERRED BY PROMINENT COMPANIES
           5.7.1 KEY INFLUENCERS
    5.8 VALUE CHAIN ANALYSIS
           FIGURE 18 MAJOR VALUE IS ADDED DURING THE MANUFACTURING AND ASSEMBLY PHASES
    5.9 ECOSYSTEM ANALYSIS OF THE IN VIVO TOXICOLOGY MARKET
           FIGURE 19 ECOSYSTEM ANALYSIS

6 IN VIVO TOXICOLOGY MARKET, BY PRODUCT (Page No. - 73)
    6.1 INTRODUCTION
           TABLE 6 IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
    6.2 CONSUMABLES
           TABLE 7 IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 8 IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY REGION, 2018–2025 (USD MILLION)
           TABLE 9 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 10 EUROPE: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 11 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 12 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES,BY COUNTRY, 2018–2025 (USD MILLION)
           6.2.1 REAGENTS & KITS
                    6.2.1.1 Reagents & kits hold the largest share of the consumables market
           TABLE 13 IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS, BY REGION, 2018–2025 (USD MILLION)
           TABLE 14 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 15 EUROPE: IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 16 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 17 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR REAGENTS & KITS, BY COUNTRY, 2018–2025 (USD MILLION)
           6.2.2 ANIMAL MODELS
           TABLE 18 IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 19 IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY REGION, 2018–2025 (USD MILLION)
           TABLE 20 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 21 EUROPE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 22 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 23 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
                    6.2.2.1 Mice models
                               6.2.2.1.1 Mice models are widely used in in vivo toxicity testing
           TABLE 24 PROMINENT MICE MODELS AVAILABLE IN THE MARKET
           TABLE 25 IN VIVO TOXICOLOGY MARKET FOR MICE MODELS, BY REGION, 2018–2025 (USD MILLION)
           TABLE 26 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR MICE MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 27 EUROPE: IN VIVO TOXICOLOGY MARKET FOR MICE MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 28 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR MICE MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 29 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR MICE MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
                    6.2.2.2 Rat models
                               6.2.2.2.1 Ease of performing surgery on rat models and development of genetically modified rat models drive the market
           TABLE 30 IN VIVO TOXICOLOGY MARKET FOR RAT MODELS, BY REGION, 2018–2025 (USD MILLION)
           TABLE 31 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR RAT MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 32 EUROPE: IN VIVO TOXICOLOGY MARKET FOR RAT MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 33 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR RAT MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 34 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR RAT MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
                    6.2.2.3 Other animal models
           TABLE 35 GUINEA PIG AND HAMSTER MODELS: ADVANTAGES AND USAGE
           TABLE 36 NON-RODENT ANIMAL MODELS: ADVANTAGES AND USAGE
           TABLE 37 IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS, BY REGION, 2018–2025 (USD MILLION)
           TABLE 38 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 39 EUROPE: IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 40 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 41 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER ANIMAL MODELS, BY COUNTRY, 2018–2025 (USD MILLION)
    6.3 INSTRUMENTS
           6.3.1 GROWING RESEARCH AND INTRODUCTION OF COMBINATION INSTRUMENTS ARE KEY GROWTH FACTORS
           TABLE 42 IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS, BY REGION, 2018–2025 (USD MILLION)
           TABLE 43 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 44 EUROPE: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 45 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS,BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 46 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS, BY COUNTRY, 2018–2025 (USD MILLION)

7 IN VIVO TOXICOLOGY MARKET, BY TEST TYPE (Page No. - 92)
    7.1 INTRODUCTION
           TABLE 47 IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
    7.2 CHRONIC TOXICITY TESTING
           7.2.1 CHRONIC TOXICITY TESTING IS ESSENTIAL FOR NEW DRUG ENTITY APPROVALS
           TABLE 48 CHRONIC TOXICITY TESTING MARKET, BY REGION, 2018–2025 (USD MILLION)
           TABLE 49 NORTH AMERICA: CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 50 EUROPE: CHRONIC TOXICITY TESTING MARKET, BY COUNTRY,2018–2025 (USD MILLION)
           TABLE 51 ASIA PACIFIC: CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 52 LATIN AMERICA: CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.3 SUB-CHRONIC TOXICITY TESTING
           7.3.1 SUB-CHRONIC TOXICITY TESTS PROVIDE DATA ON MANY PARAMETERS OF CHRONIC TOXICITY
           TABLE 53 SUB-CHRONIC TOXICITY TESTING MARKET, BY REGION, 2018–2025 (USD MILLION)
           TABLE 54 NORTH AMERICA: SUB-CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 55 EUROPE: SUB-CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 56 ASIA PACIFIC: SUB-CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 57 LATIN AMERICA: SUB-CHRONIC TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.4 SUB-ACUTE TOXICITY TESTING
           7.4.1 LONG OBSERVATION REQUIREMENTS AND HIGH ANIMAL SAMPLE SIZES ARE CHALLENGES ASSOCIATED WITH SUB-ACUTE TESTING
           TABLE 58 SUB-ACUTE TOXICITY TESTING MARKET, BY REGION, 2018–2025 (USD MILLION)
           TABLE 59 NORTH AMERICA: SUB-ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 60 EUROPE: SUB-ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 61 ASIA PACIFIC: SUB-ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 62 LATIN AMERICA: SUB-ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
    7.5 ACUTE TOXICITY TESTING
           7.5.1 DISADVANTAGES OF ACUTE TOXICITY TESTING HAVE DRIVEN USE OF ALTERNATIVES
           TABLE 63 ALTERNATIVE METHODS TO DETERMINE LD50 IN ACUTE TOXICITY TESTING
           TABLE 64 ACUTE TOXICITY TESTING MARKET, BY REGION, 2018–2025 (USD MILLION)
           TABLE 65 NORTH AMERICA: ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 66 EUROPE: ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 67 ASIA PACIFIC: ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 68 LATIN AMERICA: ACUTE TOXICITY TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION)

8 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY (Page No. - 102)
    8.1 INTRODUCTION
           TABLE 69 IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
    8.2 OUTSOURCED TESTING FACILITIES
           8.2.1 FOCUS ON COST CURTAILMENT AND NEED TO ACCESS SKILLED LABOR & EXPERTISE HAS BOOSTED OUTSOURCING
           TABLE 70 IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES, BY REGION, 2018–2025 (USD MILLION)
           TABLE 71 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 72 EUROPE: IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 73 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 74 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR OUTSOURCED TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION)
    8.3 IN-HOUSE TESTING FACILITIES
           8.3.1 HIGH COSTS OF IN-HOUSE TESTING RESTRICT MARKET GROWTH
           TABLE 75 IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY REGION, 2018–2025 (USD MILLION)
           TABLE 76 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 77 EUROPE: IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 78 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 79 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR IN-HOUSE TESTING FACILITIES, BY COUNTRY, 2018–2025 (USD MILLION)

9 IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT (Page No. - 109)
    9.1 INTRODUCTION
           TABLE 80 IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
    9.2 IMMUNOTOXICITY
           9.2.1 IMMUNOTOXICITY TESTING HOLDS THE LARGEST SHARE OF THE MARKET,BY ENDPOINT
           TABLE 81 IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY, BY REGION, 2018–2025 (USD MILLION)
           TABLE 82 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 83 EUROPE: IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 84 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 85 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR IMMUNOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
    9.3 SYSTEMIC TOXICITY
           9.3.1 SYSTEMIC TOXICITY HELPS IDENTIFY A RANGE OF PARAMETERS IN PHARMA/BIOLOGIC TESTING
           TABLE 86 IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY, BY REGION, 2018–2025 (USD MILLION)
           TABLE 87 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 88 EUROPE: IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY,BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 89 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 90 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR SYSTEMIC TOXICITY,BY COUNTRY, 2018–2025 (USD MILLION)
    9.4 CARCINOGENICITY
           9.4.1 RISING CANCER RESEARCH IS DRIVING THE MARKET FOR CARCINOGENICITY TESTING
           TABLE 91 IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY, BY REGION, 2018–2025 (USD MILLION)
           TABLE 92 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 93 EUROPE: IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 94 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 95 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR CARCINOGENICITY, BY COUNTRY, 2018–2025 (USD MILLION)
    9.5 GENOTOXICITY
           9.5.1 GENOTOXICITY TESTING HELPS ISOLATE MUTATIVE SUBSTANCES
           TABLE 96 TYPES OF GENOTOXICITY TESTS
           TABLE 97 IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY, BY REGION, 2018–2025 (USD MILLION)
           TABLE 98 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 99 EUROPE: IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 100 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 101 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR GENOTOXICITY, BY COUNTRY, 2018–2025 (USD MILLION)
    9.6 DEVELOPMENTAL & REPRODUCTIVE TOXICITY
           9.6.1 RISING PREVALENCE OF SEXUAL HEALTH & DEVELOPMENTAL ABNORMALITIES DRIVE MARKET GROWTH
           TABLE 102 IN VIVO TOXICOLOGY MARKET FOR DART, BY REGION, 2018–2025 (USD MILLION)
           TABLE 103 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR DART, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 104 EUROPE: IN VIVO TOXICOLOGY MARKET FOR DART, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 105 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR DART, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 106 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR DART, BY COUNTRY, 2018–2025 (USD MILLION)
    9.7 OTHER TOXICITY ENDPOINTS
           TABLE 107 IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY REGION, 2018–2025 (USD MILLION)
           TABLE 108 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 109 EUROPE: IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 110 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 111 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER TOXICITY ENDPOINTS, BY COUNTRY, 2018–2025 (USD MILLION)

10 IN VIVO TOXICOLOGY MARKET, BY END USER (Page No. - 124)
     10.1 INTRODUCTION
           TABLE 112 IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
     10.2 ACADEMIC & RESEARCH INSTITUTES
             10.2.1 GROWING PARTNERSHIPS AND HIGH USE OF INSTRUMENTS & CONSUMABLES DRIVE MARKET GROWTH
           TABLE 113 IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018–2025 (USD MILLION)
           TABLE 114 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 115 EUROPE: IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 116 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 117 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018–2025 (USD MILLION)
     10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
             10.3.1 GROWING IMPORTANCE OF PRECLINICAL TOXICOLOGY EVALUATION HAS INCREASED DEMAND FOR TESTING, ESPECIALLY IN PHARMA COMPANIES
           TABLE 118 IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018–2025 (USD MILLION)
           TABLE 119 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 120 EUROPE: IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 121 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 122 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018–2025 (USD MILLION)
     10.4 CONTRACT RESEARCH ORGANIZATIONS
             10.4.1 CONTRACT SERVICES HAVE REGISTERED RISING DEMAND DUE TO INCREASING COSTS OF RESEARCH
           TABLE 123 IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018–2025 (USD MILLION)
           TABLE 124 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 125 EUROPE: IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 126 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 127 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018–2025 (USD MILLION)
     10.5 OTHER END USERS
           TABLE 128 IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS, BY REGION, 2018–2025 (USD MILLION)
           TABLE 129 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 130 EUROPE: IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS,BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 131 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 132 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR OTHER END USERS,BY COUNTRY, 2018–2025 (USD MILLION)

11 IN VIVO TOXICOLOGY MARKET, BY REGION (Page No. - 135)
     11.1 INTRODUCTION
           FIGURE 20 IN VIVO TOXICOLOGY MARKET SNAPSHOT
           TABLE 133 IN VIVO TOXICOLOGY MARKET, BY REGION, 2018–2025 (USD MILLION)
     11.2 NORTH AMERICA
           FIGURE 21 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET SNAPSHOT
           TABLE 134 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 135 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 136 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 137 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 138 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 139 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 140 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 141 NORTH AMERICA: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Government funding for life sciences research drives the market growth in the US
           TABLE 142 US: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 143 US: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 144 US: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 145 US: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 146 US: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 147 US: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 148 US: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Growth in stem cell research activities expected to lead to market expansion
           TABLE 149 CANADA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 150 CANADA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 151 CANADA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 152 CANADA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 153 CANADA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 154 CANADA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 155 CANADA: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
     11.3 EUROPE
           TABLE 156 EUROPE: IN VIVO TOXICOLOGY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 157 EUROPE: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 158 EUROPE: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 159 EUROPE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 160 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 161 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 162 EUROPE: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 163 EUROPE: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.3.1 UK
                        11.3.1.1 Increasing focus on cancer research in the UK is a key market growth driver
           TABLE 164 UK: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 165 UK: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 166 UK: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 167 UK: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 168 UK: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 169 UK: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 170 UK: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.3.2 GERMANY
                        11.3.2.1 Germany accounted for the second-largest share of the European market
           TABLE 171 GERMANY: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 172 GERMANY: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 173 GERMANY: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 174 GERMANY: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 175 GERMANY: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,2018–2025 (USD MILLION)
           TABLE 176 GERMANY: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 177 GERMANY: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.3.3 FRANCE
                        11.3.3.1 Increased investments in proteomics and genomics to fuel growth of mice models
           TABLE 178 FRANCE: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 179 FRANCE: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 180 FRANCE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 181 FRANCE: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 182 FRANCE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 183 FRANCE: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 184 FRANCE: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Growth in the biotechnology and pharmaceutical industries to drive market growth
           TABLE 185 ITALY: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 186 ITALY: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 187 ITALY: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 188 ITALY: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 189 ITALY: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 190 ITALY: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 191 ITALY: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Short study start-up times and rising R&D expenditure to boost the growth of the Spanish market
           TABLE 192 SPAIN: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 193 SPAIN: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 194 SPAIN: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 195 SPAIN: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 196 SPAIN: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 197 SPAIN: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,2018–2025 (USD MILLION)
           TABLE 198 SPAIN: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.3.6 REST OF EUROPE
           TABLE 199 ROE: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 200 ROE: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 201 ROE: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 202 ROE: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 203 ROE: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 204 ROE: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 205 ROE: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
     11.4 ASIA PACIFIC
           FIGURE 22 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET SNAPSHOT
           TABLE 206 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY COUNTRY,2018–2025 (USD MILLION)
           TABLE 207 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 208 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 209 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 210 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 211 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT,2018–2025 (USD MILLION)
           TABLE 212 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 213 ASIA PACIFIC: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 International alliances for R&D are driving the market
           TABLE 214 CHINA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 215 CHINA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 216 CHINA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 217 CHINA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 218 CHINA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 219 CHINA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 220 CHINA: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Increasing focus on personalized diagnostics products to support market growth
           TABLE 221 JAPAN: IN VIVO TOXICOLOGY MARKET, BY PRODUCT,2018–2025 (USD MILLION)
           TABLE 222 JAPAN: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 223 JAPAN: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 224 JAPAN: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 225 JAPAN: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 226 JAPAN: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 227 JAPAN: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Robust growth in the biotech industry in India to boost the market growth
           TABLE 228 INDIA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 229 INDIA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 230 INDIA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 231 INDIA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 232 INDIA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 233 INDIA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 234 INDIA: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.4.4 REST OF ASIA PACIFIC
           TABLE 235 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 236 ROAPAC: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 237 ROAPAC: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 238 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 239 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 240 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 241 ROAPAC: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
     11.5 LATIN AMERICA
           TABLE 242 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY COUNTRY, 2018–2025 (USD MILLION)
           TABLE 243 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 244 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 245 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 246 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 247 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 248 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 249 LATIN AMERICA: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Growing biologics sector in the country to drive the market
           TABLE 250 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 251 BRAZIL: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 252 BRAZIL: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 253 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 254 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 255 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 256 BRAZIL: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.5.2 MEXICO
                        11.5.2.1 Favorable business environment for market players to support market growth
           TABLE 257 MEXICO: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 258 MEXICO: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 259 MEXICO: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 260 MEXICO: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 261 MEXICO: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 262 MEXICO: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY,2018–2025 (USD MILLION)
           TABLE 263 MEXICO: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
             11.5.3 REST OF LATIN AMERICA
           TABLE 264 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 265 ROLATAM: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 266 ROLATAM: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 267 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 268 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 269 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 270 ROLATAM: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
             11.6.1 INFRASTRUCTURAL DEVELOPMENT TO CONTRIBUTE TO MARKET GROWTH IN THE MEA
           TABLE 271 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY PRODUCT, 2018–2025 (USD MILLION)
           TABLE 272 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET FOR CONSUMABLES, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 273 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY TYPE, 2018–2025 (USD MILLION)
           TABLE 274 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TEST TYPE, 2018–2025 (USD MILLION)
           TABLE 275 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TOXICITY ENDPOINT, 2018–2025 (USD MILLION)
           TABLE 276 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY TESTING FACILITY, 2018–2025 (USD MILLION)
           TABLE 277 MIDDLE EAST & AFRICA: IN VIVO TOXICOLOGY MARKET, BY END USER, 2018–2025 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 194)
     12.1 INTRODUCTION
     12.2 MARKET SHARE ANALYSIS (2019)
           FIGURE 23 IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS, BY KEY PLAYER, 2019
             12.2.1 ENVIGO (US)
     12.3 MARKET RANKING ANALYSIS
           FIGURE 24 COMPANY RANKING IN THE IN VIVO TOXICOLOGY INSTRUMENTS MARKET, 2019
     12.4 MARKET EVALUATION FRAMEWORK (ANIMAL MODELS)
           TABLE 278 MARKET EVALUATION FRAMEWORK: PRODUCT LAUNCHES WAS THE MAJOR STRATEGY ADOPTED BY PLAYERS
     12.5 COMPETITIVE SCENARIO
             12.5.1 KEY PRODUCT LAUNCHES
             12.5.2 KEY ACQUISITIONS
             12.5.3 KEY COLLABORATIONS
             12.5.4 KEY EXPANSIONS
     12.6 MARKET EVALUATION FRAMEWORK (INSTRUMENTS)
             12.6.1 KEY MARKET DEVELOPMENTS
                        12.6.1.1 Product launches
                        12.6.1.2 Acquisitions
                        12.6.1.3 Partnerships, collaborations, and agreements
                        12.6.1.4 Expansions
     12.7 COMPANY PRODUCT FOOTPRINT
           TABLE 279 PRODUCT PORTFOLIO ANALYSIS: IN VIVO TOXICOLOGY MARKET (ANIMAL MODELS)
     12.8 COMPANY GEOGRAPHIC FOOTPRINT
           TABLE 280 GEOGRAPHIC REVENUE MIX: IN VIVO TOXICOLOGY MARKET (2019)
     12.9 REVENUE ANALYSIS OF KEY MARKET PLAYERS
           FIGURE 25 REVENUE ANALYSIS: IN VIVO TOXICOLOGY MARKET (2019)
     12.10 COMPETITIVE LEADERSHIP MAPPING: IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS
             12.10.1 STARS
             12.10.2 EMERGING LEADERS
             12.10.3 PERVASIVE PLAYERS
             12.10.4 PARTICIPANTS
           FIGURE 26 IN VIVO TOXICOLOGY MARKET FOR ANIMAL MODELS: COMPANY EVALUATION MATRIX, 2019
     12.11 COMPETITIVE LEADERSHIP MAPPING: IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS
             12.11.1 STARS
             12.11.2 EMERGING LEADERS
             12.11.3 PERVASIVE PLAYERS
             12.11.4 PARTICIPANTS
           FIGURE 27 IN VIVO TOXICOLOGY MARKET FOR INSTRUMENTS: COMPANY EVALUATION MATRIX, 2019

13 COMPANY PROFILES (Page No. - 208)
     13.1 MAJOR PLAYERS
(Business Overview, Products Offered, Recent Developments, MnM View)* 
             13.1.1 CHARLES RIVER LABORATORIES
           TABLE 281 CHARLES RIVER LABORATORIES: BUSINESS OVERVIEW
           FIGURE 28 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT (2019)
             13.1.2 THE JACKSON LABORATORY
           TABLE 282 THE JACKSON LABORATORY: BUSINESS OVERVIEW
           FIGURE 29 THE JACKSON LABORATORY: COMPANY SNAPSHOT (2019)
             13.1.3 ENVIGO
           TABLE 283 ENVIGO: BUSINESS OVERVIEW
             13.1.4 TACONIC BIOSCIENCES
           TABLE 284 TACONIC BIOSCIENCES, INC.: BUSINESS OVERVIEW
             13.1.5 GENOWAY
           TABLE 285 GENOWAY: BUSINESS OVERVIEW
           FIGURE 30 GENOWAY: COMPANY SNAPSHOT (2019)
             13.1.6 HARBOUR BIOMED
           TABLE 286 HARBOUR BIOMED: BUSINESS OVERVIEW
             13.1.7 CROWN BIOSCIENCE
           TABLE 287 CROWN BIOSCIENCE, INC.: BUSINESS OVERVIEW
             13.1.8 TRANSCURE BIOSERVICES
           TABLE 288 TRANSCURE BIOSERVICES: BUSINESS OVERVIEW
             13.1.9 OZGENE PTY LTD.
           TABLE 289 OZGENE PTY LTD.: BUSINESS OVERVIEW
             13.1.10 THERMO FISHER SCIENTIFIC
           TABLE 290 THERMO FISHER SCIENTIFIC, INC.: BUSINESS OVERVIEW
           FIGURE 31 THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT (2019)
             13.1.11 DANAHER CORPORATION
           TABLE 291 DANAHER CORPORATION: BUSINESS OVERVIEW
           FIGURE 32 DANAHER CORPORATION: COMPANY SNAPSHOT (2019)
             13.1.12 AGILENT TECHNOLOGIES
           TABLE 292 AGILENT TECHNOLOGIES: BUSINESS OVERVIEW
           FIGURE 33 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2019)
             13.1.13 WATERS CORPORATION
           TABLE 293 WATERS CORPORATION: BUSINESS OVERVIEW
           FIGURE 34 WATERS CORPORATION: COMPANY SNAPSHOT (2019)
             13.1.14 SHIMADZU CORPORATION
           TABLE 294 SHIMADZU CORPORATION: BUSINESS OVERVIEW
           FIGURE 35 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2019)
             13.1.15 BIO-RAD LABORATORIES
           TABLE 295 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
           FIGURE 36 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2019)
             13.1.16 BRUKER CORPORATION
           TABLE 296 BRUKER CORPORATION: BUSINESS OVERVIEW
           FIGURE 37 BRUKER CORPORATION: COMPANY SNAPSHOT (2019)
             13.1.17 PERKINELMER
           TABLE 297 PERKINELMER, INC.: BUSINESS OVERVIEW
           FIGURE 38 PERKINELMER, INC.: COMPANY SNAPSHOT (2019)
     13.2 OTHER PLAYERS
             13.2.1 MERCK KGAA
           TABLE 298 MERCK KGAA: BUSINESS OVERVIEW
           FIGURE 39 MERCK KGAA: COMPANY SNAPSHOT (2019)
             13.2.2 GE HEALTHCARE
           TABLE 299 GE HEALTHCARE: BUSINESS OVERVIEW
           FIGURE 40 GE HEALTHCARE: COMPANY SNAPSHOT (2019)
             13.2.3 JANVIER LABS
           TABLE 300 JANVIER LABS: BUSINESS OVERVIEW
             13.2.4 INGENIOUS TARGETING LABORATORY
           TABLE 301 INGENIOUS TARGETING LABORATORY: BUSINESS OVERVIEW
             13.2.5 POLYGENE
           TABLE 302 POLYGENE: BUSINESS OVERVIEW
             13.2.6 GVK BIO
           TABLE 303 GVK BIO: BUSINESS OVERVIEW
             13.2.7 CYAGEN BIOSCIENCES
           TABLE 304 CYAGEN BIOSCIENCES: BUSINESS OVERVIEW
             13.2.8 DATA SCIENCES INTERNATIONAL
           TABLE 305 DATA SCIENCE INTERNATIONAL: BUSINESS OVERVIEW
     *Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies. 

14 APPENDIX (Page No. - 269)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 RELATED REPORTS
     14.4 AUTHOR DETAILS

This market research study involved extensive use of secondary sources, directories, and databases to identify and collect information useful for this technical, market-oriented, and financial study of the global in vivo toxicology market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify critical qualitative and quantitative information and to assess market prospects. The size of the in vivo toxicology market was estimated through various secondary research approaches and triangulated with inputs from primary research to arrive at the final market size.

Secondary Research

The secondary sources referred to for this research study include publications from the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), US Food and Drug Administration (FDA), World Bank, World Health Organization (WHO), United States Environmental Protection Agency (USEPA), National Institute of Environmental Health Sciences (NIEHS), Association of Assessment and Accreditation of Laboratory Animal Care (AAALAC), Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH), Federation of European Toxicologists and European Societies of Toxicology (EUROTOX), Institute of Laboratory Animal Sciences (ILAS), National Council for the Control of Animal Experimentation (CONCEA), Organisation for Economic Co-operation and Development (OECD), and the World Bank. Secondary sources also include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. Secondary data was collected and analyzed to arrive at the overall size of the global in vivo toxicology market, which was validated through primary research

Primary Research

Extensive primary research was conducted after acquiring basic knowledge about the global in vivo toxicology market scenario through secondary research. Several primary interviews were conducted with market experts from both the demand side (such as personnel from pharmaceutical and biopharmaceutical industries) and the supply side (such as C-level and D-level executives, business heads, marketing and sales managers of key manufacturers, and distributors) across five major regions—North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, online surveys, personal interviews, and telephonic interviews

In Vivo Toxicology Market   Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The market size estimates and forecasts provided in this study are derived through a mix of the bottom-up approach (revenue share analysis of leading players) and top-down approach (assessment of utilization/adoption/penetration trends, by product, test type, testing facility, toxicity endpoint, end user,company type, and region).

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed, wherever applicable, to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Objectives

  • To define, describe, and measure the global in vivo toxicology market based on product, test type, testing facility, toxicity endpoint, end user, and region
  • To provide detailed information regarding the major factors, such as drivers, restraints, opportunities, and challenges, influencing the growth of the market
  • To strategically analyze the micromarkets1 with respect to individual growth trends, prospects, and contributions to the global in vivo toxicology market
  • To analyze the opportunities in the global in vivo toxicology market for key stakeholders and provide details of the competitive landscape for major market leaders
  • To forecast the size of the market segments with respect to five main regions: North America, Europe, Asia Pacific, Latin America and Middle East & Africa
  • To profile the key players and comprehensively analyze their core competencies2 in terms of key developments, product portfolios, and financials
  • To track and analyze competitive developments such as partnerships, agreements, alliances, joint ventures, collaborations, product launches, expansions, acquisitions, grants/funds, and licensing agreements, among others, in the in vivo toxicology market

Available Customizations:

With the given market data, MarketsandMarkets offers customizations as per the client’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to 5)
COVID-19

Get in-depth analysis of the COVID-19 impact on the In Vivo Toxicology Market

Benchmarking the rapid strategy shifts of the Top 100 companies in the In Vivo Toxicology Market

Request For Special Pricing
Report Code
BT 6000
Published ON
Mar, 2021
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the In Vivo Toxicology Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2021 MarketsandMarkets Research Private Ltd. All rights reserved